Jordan Green, Herschel L. Seder Professor of Biomedical Engineering John Hopkins University

Dr. Jordan J. Green is the Herschel L. Seder Professor of Biomedical Engineering, Ophthalmology, Neurosurgery, Oncology, Materials Science & Engineering, and Chemical & Biomolecular Engineering at Johns Hopkins University. He is the Vice Chair for Research and Translation in Biomedical Engineering and is the former Director of the Biomedical Engineering Undergraduate Program at JHU. Dr. Green is also the founding Associate Director of the Translational Tissue Engineering Center and the founding Associate Director of the Translational Immunoengineering Center at JHU. Dr. Green received his B.S. in Chemical Engineering and in Biomedical Engineering from Carnegie Mellon University in 2003 and completed his Ph.D. in 2007 in Biological Engineering from MIT. Subsequently, Dr. Green was a postdoctoral associate at MIT from 2007-2008. Dr. Green was the founding CEO of the biotech company AsclepiX Therapeutics, a company that is now in clinical trials for a new peptide-based treatment for age-related macular degeneration, and currently serves as a member of the Board of Directors. He also co-founded and/or serves on the board of five other biotechnology companies. He is a Fellow of the National Academy of Inventors, the Biomedical Engineering Society, the American Institute for Medical and Biological Engineering, and the Controlled Release Society. He is also an Associate Editor at Science Advances and a standing member of the NIH Drug and Biologic Therapeutic Delivery (DBTD) study section. His work has resulted in the publication of over 175 scientific papers, 86 issued or pending patents, and 130 invited talks, and he has received numerous awards including the AIChE Colburn Award, the BMES Rita Schaffer Award, the Presidential Early Career Award for Scientists and Engineers, Popular Science’s Brilliant Ten, and was a National Academy of Medicine Emerging Leader Scholar in Health & Medicine. Dr. Green’s research focuses on the design of biotechnologies for cellular engineering. He and his lab design and synthesize new biomaterials and nanoparticle systems that can deliver biomolecules such as nucleic acids, peptides, proteins, sugars, and small molecules specifically to various cell types, including cancer cells, immune cells, and stem cells. His lab works to create innovative technologies and therapeutics that can directly benefit human health.